A combination of nivolumab and ipilimumab has demonstrated favorable 5‐year survival rates, even among patients with a PD‐L1 tumor proportion score (TPS) of < 1%, who respond less frequently to PD‐1/PD‐L1 inhibitors [14]. This evidence concerns the gene CD274 and neoplasm.